Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...

Amgen (AMGN) is expected to deliver a year ... This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates ...

The Dow Jones Industrial Average finished with a gain of 317.24 points, or 0.7%, at 44,873.28, led by gains for Amgen, Goldman Sachs, Sherwin-Williams and Nvidia. The S&P 500 ended 23.60 points higher ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Complete recombination map of the human-genome, a major step in genetics Scientists at deCODE genetics/Amgen have constructed ...

according to the company. Despite that assessment, shares in Amgen lost nearly 5% of their value after the top-line data was announced, which analysts suggested could be a consequence of high ...

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

Every year, a health care think tank called the Lown Institute ranks the 10 worst examples of "profiteering and dysfunction" ...